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Objective To determine whether the application of occlusive wrap applied immediately after birth will reducemor-
tality in very preterm infants.
Study design This was a prospective randomized controlled trial of infants born 24 0/7 to 27 6/7 weeks’ gestation
who were assigned randomly to occlusive wrap or no wrap. The primary outcome was all cause mortality at
discharge or 6 months’ corrected age. Secondary outcomes included temperature, Apgar scores, pH, base deficit,
blood pressure and glucose, respiratory distress syndrome, bronchopulmonary dysplasia, seizures, patent ductus
arteriosus, necrotizing enterocolitis, gastrointestinal perforation, intraventricular hemorrhage, cystic periventricular
leukomalacia, pulmonary hemorrhage, retinopathy of prematurity, sepsis, hearing screen, and pneumothorax.
Results Eight hundred one infants were enrolled. There was no difference in baseline population characteristics.
There were no significant differences in mortality (OR 1.0, 95% CI 0.7-1.5). Wrap infants had statistically significant
greater baseline temperatures (36.3C wrap vs 35.7C no wrap, P < .0001) and poststabilization temperatures
(36.6C vs 36.2C, P < .001) than nonwrap infants. For the secondary outcomes, there was a significant decrease
in pulmonary hemorrhage (OR 0.6, 95%CI 0.3-0.9) in thewrap group and a significant lowermean oneminute Apgar
score (P = .007) in the wrap group. The study was stopped early because continued enrollment would not result in
the attainment of a significant difference in the primary outcome.
Conclusion Application of occlusive wrap to very preterm infants immediately after birth results in greater mean
body temperature but does not reduce mortality. (J Pediatr 2015;166:262-8).
or more than 40 years, hypothermia has been recognized as an independent risk factor for death in newborn infants.1-11
Despite modern resuscitation techniques, 40%-65% of premature newborns still experience hypothermia, and it remainsFrom the 1Women and Babies Program, Sunnybrook
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infants are particularly vulnerable to heat loss because of immature, keratin-
deficient skin without subcutaneous fat, poor vasomotor control, and increased
surface area to body weight ratio.11,14-16 Besides an increased risk of mortality,
other complications associated with neonatal hypothermia include morbidity
from acidosis, delayed transition from fetal to newborn circulation, abnormal
coagulation, infection, and respiratory distress syndrome.2
The application of occlusive wrap immediately after birth can reduce immedi-
ate postnatal evaporative heat loss. In a systematic review, Cramer et al17 evalu-
ated 3 small, randomized controlled trials and 5 trials using historical controls
that studied the use of occlusive wrap immediately after birth in infants born
at less than 33 weeks’ gestation. They concluded that infants wrapped immedi-
ately after birth had significantly greater admission temperatures compared
with nonwrapped infants and that wrapping significantly reduced the incidence
of hypothermia. The systematic review did not show a significant difference in
mortality between wrapped and unwrapped infants. An adequately powered,
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Vol. 166, No. 2  February 2015the use of wrapping immediately after delivery would result
in a difference in mortality.
Methods
We hypothesized that polyethylene occlusive wrap applied
immediately after delivery to infants born at 24 0/7 to 27 6/
7 weeks’ gestation would result in decreased mortality
compared with the conventional method of drying and ther-
mal management.
We conducted a multicenter RCT at 39 participating Ver-
mont Oxford Network (VON) centers. All participating cen-
ters received a training package and participated in a
teleconference to ensure familiarity with the study protocol
and procedures before patients were enrolled. Detailed
methods have been published previously.18
Primary Outcome and Secondary Outcomes
The primary outcome was all-cause mortality occurring
before discharge from the hospital or 6 months’ corrected
age, whichever came first. We attempted to collect primary
outcome data on infants transferred to other institutions.
Trial infants who remained hospitalized at 6 months’ cor-
rected age were coded as being alive.
Secondary outcomes included baseline temperature taken
after cardiorespiratory stabilization if admitted directly to the
neonatal intensive care unit or after arrival in the neonatal
intensive care unit if immediate resuscitation took place in
the delivery room (DR), and poststabilization temperature
taken after admission procedures were completed and the in-
fant was left to rest in a stable thermoneutral environment.
Other secondary outcomes included Apgar scores, pH, base
deficit, and blood pressure and blood glucose. The incidence
of common complications of prematurity, including respira-
tory distress syndrome, bronchopulmonary dysplasia, sei-
zures, patent ductus arteriosus (PDA), necrotizing
enterocolitis, gastrointestinal perforation, intraventricular
hemorrhage, cystic periventricular leukomalacia, pulmonary
hemorrhage, retinopathy of prematurity, sepsis, failed hear-
ing screen, and pneumothorax were compared.19
All temperatures were axillary and taken with a standard-
ized thermometer (Medline Digital Thermometer, Munde-
lein, Illinois). Rectal temperatures were optional and only
taken when infants were not wrapped. Axillary temperature
on wrapped infants was taken over the wrap to prevent open-
ing the wrap and potential cooling of the infant.
Statistical Analyses
Analysis was performed on an intention-to-treat basis. Base-
line mortality data from VON for inborn infants 24 0/7 to 27
6/7 weeks’ gestation in the calendar year 2002 was 22.7%. To
detect a 25% relative risk reduction from 22.7% to 17% at
80% power and alpha of 0.05, enrollment of 802 infants in
each group was planned.
Permuted variable block randomization lists using
random-number generating software were produced. Sepa-
rate independent randomization lists were created for eachsite and each gestational age (GA) stratum (stratum 1: 24
0/7 weeks to 25 6/7 weeks; stratum 2: 26 0/7 weeks to 27 6/
7 weeks). Group allocation was 1:1.
Descriptive statistics were calculated for all variables of
interest. Continuous measures were summarized via
mean and SD, whereas categorical measures were summa-
rized by the use of the count and percentage. The primary
outcome of mortality was assessed between groups using a
logistic model adjusting for the correlation among obser-
vations taken at the same site. Results were reported
with OR and their associated 95% CI. Secondary outcomes
were compared between groups using c2 analyses or t tests,
depending on whether the outcome measure was categor-
ical or continuous. A logistic regression model was run to
assess differences in mortality between groups adjusting
for predictors of interest (GA, sex, method of delivery,
antenatal steroids, race, and birth weight) as well as the
correlation among observations taken at the same site.
All analyses were run across the entire sample as well as
separately by stratum. All analyses used SAS Version 9.2
(SAS Institute, Cary, North Carolina). A trend of test anal-
ysis was run to compare the distribution of baseline and
poststabilization temperatures in wrap and no wrap in-
fants in predetermined temperature ranges.
Results
Infants from 39 VON centers were enrolled between
November 2004 and June 2010. The number of eligible in-
fants and the number assigned to each group are in
Figure 1. Stratum 1 (24 0/7 to 25 6/7 weeks’ gestation)
included 366 infants and stratum 2 (26 0/7 to 27 6/7 weeks’
gestation) included 435 infants.
All sites were offered the option to apply to their local
institutional research board for permission to use a waiver
of consent or delayed consent. Four sites, 1 Canadian and
3 US, applied and received approval. The Canadian site al-
lowed any infant who was born within the first 24 hours of
maternal admission to the hospital to be enrolled under
delayed consent. When appropriate, consent then had to
be obtained to submit data collected during the study
period and to continue with the study. All other infants
had to be enrolled under informed consent. The US sites
were approved to use a waiver of consent or delayed con-
sent at any time. The families of all infants enrolled in the
study under a delay/waiver of consent were informed of
the study, and any infant enrolled at any time (under
informed, waiver or delayed consent) was allowed to be
removed from the study if the parent(s) wished. Eighty-
three percent (668) of the infants were enrolled under
informed consent, and 17% (133) were enrolled under de-
layed/waiver of consent.
Interim analyses for safety were performed at 25% enroll-
ment, and for safety and futility at 50% enrollment of the
projected sample size. The futility analysis determined that
even if the full sample size were enrolled, the study would
not achieve its goal of demonstrating a 25% relative risk263
Figure 1. Number of infants who were eligible for the study and randomly assigned to the wrap or no-wrap group.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 166, No. 2reduction in the primary outcome. Consequently, the Data
and Safety Monitoring Board recommended halting enroll-
ment, and the Heat Loss Prevention (HeLP) Trial Steering
Committee closed enrollment June 30, 2010.
There were no statistically significant differences in the
maternal or neonatal characteristics between groups
(Table I). The mean temperature of the DR for the wrap
group was 23.5C (range 16.1C to 36C) compared with
23.3C for the no-wrap group (range 15C to 32.2C).
Mortality data were available for 799 of the 801 infants.
There was no significant difference in mortality between
the 2 groups with 83 deaths (20.5%) in the wrap group and
79 deaths (20%) in the no-wrap group (OR 1.0, 95% CI
0.7-1.5, Table II; available at www.jpeds.com). After
adjustment for variables that could impact on the risk of264death (GA, sex, method of delivery, birth weight, race,
antenatal steroids), logistic regression analysis revealed that
the difference between groups remained nonsignificant
(OR 0.9, 95% CI 0.6-1.3).
In infants 24 0/7 to 25 6/7 weeks’ gestation (stratum 1),
26.1% of the wrap group died compared with 33.2% of the
no-wrap group (OR 0.7, 95% CI 0.5-1.1; Table II). In
infants 26 0/7 to 27 6/7 weeks’ gestation (stratum 2),
15.7% of the wrap group died compared with 9.2% of
the no-wrap group (OR 1.8, 95% CI 1.0-3.3). After
adjustment for variables that could impact the risk of
death, logistic regression analysis revealed that the
difference between groups was no longer statistically
significant (stratum 1: OR 0.66, 95% CI 0.40-1.1 and
stratum 2: OR 1.6, 95% CI 0.8-3.0).Reilly et al




Prenatal care 390/403 (97%) 382/397 (96%)
Any antenatal steroids 375/403 (93%) 370/395 (94%)
Vaginal delivery 123/404 (30%) 129/397 (33%)
Rupture of membranes
>24 h
113/399 (28%) 130/391 (33%)




36.9 (33.7-39.7) 36.9 (34.6-39.5)
Neonatal characteristics
Birth weight 800  205 (SD) 821  199 (SD)
GA in weeks, mean 25.6 26.0
Sex
Male 208/404 (51%) 219/397 (55%)
Race
Asian 48/402 (12%) 41/396 (10%)
Black 106/402 (26%) 112/396 (28%)
Native American 0/402 (0%) 2/396 (<1%)
White 230/402 (57%) 226/396 (57%)
Other 18/402 (5%) 15/396 (4%)
Hispanic 47/404 (12%) 42/397 (11%)
Maternal education: less
than high school
76/368 (21%) 71/367 (19%)
Multiple birth 75/404 (19%) 84/397 (21%)
February 2015 ORIGINAL ARTICLESFor the secondary outcomes, there was a significantly
lower mean 1-minute Apgar score (P = .007) in the wrap
group but no differences in the 5- or 10-minute Apgar scores.
The median one minute Apgar score was 5 with a lower and
upper quartile range of 3-7 for both wrap and no-wrap
groups. There was also a statistically significant decrease in
pulmonary hemorrhage (OR 0.6, 95% CI 0.3-0.9) in the
wrap group (Table III; available at www.jpeds.com). In the
lower GA stratum there was a statistically significant
decrease in the risk of treated PDA (OR 0.6, 95% CI 0.4-
0.99) and pulmonary hemorrhage (OR 0.4, 95% CI 0.2-0.8)
in the wrap group. This difference was not seen in the
infants randomized to stratum two. There were no other
differences between the groups.
Infants randomized to the wrap group were wrapped at a
mean time of 24 seconds after birth with the wrap being
removed at a mean time of 84 minutes after birth. There
was no difference between groups in the length of time spent
in the DR (wrapped infants, 16 minutes; no-wrap infants,
16 minutes).
Infants randomized to the wrap group had significantly
greater mean baseline temperature (36.3C) compared with
the no-wrap group (35.7C) (P < .0001) as well as signifi-
cantly greater mean poststabilization temperature for the
wrap group (36.6C) compared with the no-wrap group
(36.2C) (P < .0001).
Figure 2 shows the distributions of baseline and
poststabilization temperatures for wrap and no wrap
infants. With regard to severe hypothermia, 51 infants
(7.2%) had a baseline temperature <34.5C. The majority
of these infants (42, or 82%) were in the no-wrap group;
35 infants (4.6%) had a poststabilization temperatureRandomized Trial of Occlusive Wrap for Heat Loss Prevention in<34.5C, and the majority of these infants (23, or 66%)
were also in the no-wrap group.
With regard to hyperthermia, 32 infants (4.5%) had a
baseline temperature $37.5C; the majority of these infants
(28, or 88%) were in the wrap group. Sixty-one infants
(8%) had a poststabilization temperature $37.5C; the ma-
jority of these infants (43, or 70%) also were in the wrap
group. DR temperature did not seem to contribute to the
risk of hyperthermia. Wrapped infants resuscitated in a DR
with a temperature >25C were as likely to have a baseline
temperature >38.0C as wrapped infants resuscitated in a
DR with a temperature <25C (P = .10).
A trend of test analysis of the temperature distributions in
both groups indicated a highly significant difference over
temperature categories between groups (P < .0001) for
both baseline and poststabilization temperatures, with no-
wrap infants trending to be colder and wrap infants trending
to be warmer in all temperature categories. There was a
marginally significant difference in mortality favoring the
no-wrap group in infants who had a baseline temperature be-
tween 35.5C and 36.4C (19.4% for the wrap group and
11.3% for the no-wrap group, P = .05). There were no statis-
tically significant differences in mortality between the wrap
and no-wrap groups for all other baseline and poststabiliza-
tion temperature ranges.
Forty-three protocol violations were recorded for 37 infants
in the no-wrap group, with the most common being the use of
an adjunct heat source when the temperature was not known
to be less than 35.5C (n = 17), randomization card pulled out
of sequence (n = 9), or infant wrapped after birth (n = 10).
One hundred eighty-five protocol violations were recorded
for 114 infants in the wrap group, including delayed applica-
tion of wrap (n = 43), wrap opened (n = 42), wrap removed
early (n = 18), use of adjunct heat source when the tempera-
ture was not known to be less than 35.5C (n = 12), random-
ization card pulled out of sequence or lost (n = 14), and infant
dried before wrap applied (n = 1).
Discussion
Even though the application of occlusive wrap to very pre-
term infants improved baseline and poststabilization body
temperatures compared with standard management, there
was no associated improvement in all-cause mortality. There
were also no differences in the secondary outcomes except for
the 1-minute Apgar score and pulmonary hemorrhage. In
stratum 1 (24 0/7 to 25 6/7), there was a significant increase
in both pulmonary hemorrhage and treated PDA in the no-
wrap group. It is plausible that the increase in pulmonary
hemorrhage in the no-wrap group could have been directly
related to the increase in hypothermia, mediated via hemo-
dynamic, metabolic, and/or hematologic effects. However,20
this association must be considered speculative because this
was one of many secondary outcomes.
The differences in mortality in both strata were lost after lo-
gistic regression. Because this study was not powered to detect
a difference in mortality within strata, we cannot be sure thatPreterm Infants 265
Figure 2. Distribution of baseline and poststabilization temperature in infants assigned to wrap and no-wrap groups.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 166, No. 2there is no lifesaving benefit accrued by wrapping infants born
at less than 25 6/7 weeks’ gestation. The results indicate that
such benefits may be greatest in the smallest, most premature
infants. Similarly, we cannot be sure that there is not a poten-
tial lifesaving benefit in not wrapping infants born 26 0/7 to
27 6/7 weeks’ gestation although this would seem unlikely.
Knobel et al21 found that warmer DRs were associated with
greater admission temperatures and that only the subgroup
of infants who were both delivered in a warm DR and wrap-
ped had a mean admission temperature >36.4C. The World
Health Organization22 guidelines recommend that the mini-
mum temperature in the DR be 25C. This was rarely
achieved in this study. Our data show that 86% of the infants
enrolled received their initial resuscitation in a room with a
temperature #25C. Eleven percent of the no-wrap infants
received their initial resuscitation in a room with a tempera-
ture >25C compared with 17% of the infants randomized to
the wrap group. There was no difference inmortality noted in
these infants resuscitated in a warmer DR environment.
The possible association between duration of the wrap place-
ment andmortalitywas analyzed, and therewas no difference inFigure 3. Mortality rates of all infants according to baseline and
266the duration of wrap between those infants who survived and
those who died (P = .64). Similar results were obtained for
both age strata (stratum 1, P = .59; stratum 2, P = .79).
With regard to hyperthermia, the majority of infants who
had a baseline and post stabilization temperature $37.5C
were in the wrap group (28/32 baseline and 43/61 poststabi-
lization). The risk of hyperthermia was unrelated to the DR
temperature. The number of participants in these hyperther-
mia analyses was quite small; therefore, it is impossible to
speculate on any potential adverse effects of postnatal hyper-
thermia for wrapped infants.
Figure 3 shows the mortality rates for each temperature
range for baseline and poststabilization temperatures. The
greatest mortality rates were in the severely hypothermic
infants with the rates steadily decreasing as temperatures
increased. Mortality rates for infants who are hypothermic
at poststabilization are greater, suggesting that hypothermic
infants who remain hypothermic during the course of their
resuscitation have increased odds of dying.
This study had several limitations. The study was stopped at
50% enrollment. Early closure may be recommended andpoststabilization temperature.
Reilly et al
February 2015 ORIGINAL ARTICLESacceptable in large neonatal clinical trials due to futility,23
safety,24 or slow enrollment.25,26 Regardless, this is the largest
RCT evaluating the short-term effects of wrapping infants
born between 24 0/7 and 27 6/7 weeks’ gestation immediately
after birth andoffers a significant addition to the body of knowl-
edge on this subject. Even if the trial had progressed beyond
50% enrollment, futility analysis revealed that we would not
have achieved our 25%relative risk reduction goal formortality.
Another limitation is the number of reported protocol vi-
olations. This was a large pragmatic trial with 39 participating
centers. Not surprisingly, the majority of the protocol viola-
tions occurred in the treatment group rather than in the stan-
dard of care group. The most common protocol violations in
the wrap group that could have affected the temperature of
the infants were delayed application of the wrap, wrap
opened during the study period, and early removal of the
wrap. Despite these violations, infants in the wrap group still
demonstrated significantly greater baseline and poststabiliza-
tion temperatures than the no-wrap infants, suggesting that
the wrap violations may not have greatly affected heat loss.
Another common protocol violation was the use of an
adjunct heat source when the temperature was not known
to be less than 35.5C. These infants could have been hypo-
thermic, normothermic, or hyperthermic at the time of the
application of the heat source. Only 12 infants in the wrap
group experienced this violation, and 17 infants in the no-
wrap group experience this violation. The numbers are small
and occurred in both groups, suggesting that any distortion
of the significance of the secondary outcome of temperature
and the primary outcome of mortality is unlikely.
Another limitation may be the method of consent and
enrollment. Informed consent for resuscitation trials is prob-
lematic and may result in selection bias and nongeneralizabil-
ity of the results.27,28 Ethical options for enrolling participants
without individual informed consent, such as a waiver
approved by the institutional review board or delay of consent,
were used within some centers participating in the HeLP Trial
and may pose a solution for this research barrier.
The application of occlusive wrap in infants born 24 0/7 to
27 6/7 weeks’ gestation reduced the overall incidence of hy-
pothermia but did not reduce mortality or other selected
complications of prematurity. Our data show that hypother-
mia remains a problem for infants born 24 0/7 to 27 6/
7 weeks’ gestation, that mortality rates increase with the
severity of hypothermia, and that wrapping had no strong
significant benefit on reducing mortality. We speculate that
hypothermia may be a marker for increased risk of death
but wrapping is not an effective intervention to reduce hypo-
thermia associated death. This may be especially true in in-
fants who continue to lose heat during the stabilization
period despite adequate environmental thermal care. n
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Infants in Kotzebue, Alaska
McAlister R, Brody JA, Overfield TM. J Pediatr 1965;66:343-8
It was known in the 1960s that diarrheal diseases were prevalent and were associated with substantial morbidity andmortality in rural Alaska. Identified etiologies primarily were Shigella and Salmonella species. High burden of dis-
ease was attributed to multiple factors, most importantly vulnerable clean water sources, lack of running water in
homes, and poor handling of septic waste. The role of Escherichia coli was not documented. McAlister et al performed
serotyping on stool isolates of E coli to identify enteropathogenic strains (EPEC) from 91 patients admitted to the
Alaska Native Hospital in Kotzebue for diarrhea over a 12-month period from 1962-1963. A striking 44% had
EPEC as the only pathogen identified; EPEC was the predominant pathogen identified in infants <1 year of age.
The authors acknowledge inability to definitively ascribe illness to the E coli isolate (which predominantly was E
coli 0111:B4); carriage rate in another study of healthy individuals was 6%. This study was the first to describe a sub-
stantial potential pathogenic role for EPEC in the Far North.Water and sewage handling in Kotzebue at the time of the
study was delineated. Clean water sources were from melted ice or hauling of river water (in summer). Human waste
was disposed of by use of “honey buckets,” which were emptied into a garbage truck and dumped into the sea or adja-
cent rivers.
There is renewed interest in E coli as a pathogen of diarrheal disease because modern molecular assays can identify
organisms containing a variety of virulence factors. Undoubtedly, the pathogenic role of E coli has been underesti-
mated to date. Fifty years later, lack of piped clean water into homes and waste disposal out continue to be identified
as underpinnings of the excessive burden of respiratory and gastrointestinal infections in indigenous Alaskan popu-
lations.
Sarah S. Long, MD
Department of Pediatrics
St. Christopher’s Hospital for Children
Philadelphia, Pennsylvania
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Table II. Primary outcome for infants assigned to the wrap and no wrap groups
Mortality Wrap No wrap OR (95% CI) P value
All infants 83/404 (20.5%) 79/395 (20.0%) 1.0 (0.7-1.5) .85
Stratum 1: 24 0/7 to 25 6/7 49/188 (26.1%) 59/178 (33.2%) 0.7 (0.5-1.1) .14
Stratum 2: 26 0/7 to 27 6/7 34/216 (15.7%) 20/217 (9.2%) 1.8 (1.0-3.3) .04
Table III. Secondary outcomes of infants assigned to the wrap and no-wrap groups
Secondary outcomes Wrap No wrap P value OR (95% CI)
Apgar scores (mean)
1 min 4.68  2.3 5.12  2.3 .007
5 min 7.05  2.0 7.30  1.8 .11
10 min 7.31  2.3 7.33  2.2 .67
RDS 373/404 (92%) 363/396 (92%) .73 1.09 (0.7-1.08)
Treated PDA 192/401 (48%) 209/394 (53%) .14 0.8 (0.6-1.1)
IVH
Any 143/378 (38%) 148/375 (40%) .97 0.95 (0.6-1.45)
Severe (3 and 4) 45/378 (12%) 45/375 (12%) 0.97 (0.5-1.8)
Cystic PVL 17/376 (5%) 21/375 (6%) .50 0.78 (0.41-1.50)
Pulmonary hemorrhage 27/403 (7%) 44/393 (11%*) .03 0.6 (0.3-0.9)
GI perforation 23/402 (6%) 18/393 (5%) .47 1.3 (0.7-2.4)
NEC (stage 2 or more) 34/403 (8%) 35/394 (9%) .82 0.9 (0.6-1.5)
ROP, severe (stage 3 or greater) 58/305 (19%) 57/301 (19%) .98 1.0 (0.7-1.5)
Bacterial sepsis (early) 16/401 (4%) 22/394 (6%) .29 0.7 (0.4-1.4)
Sepsis and/or meningitis late (any bacterial) 78/373 (21%) 93/369 (25%) .16 0.8 (0.5-1.1)
Sepsis and/or meningitis late (coagulase negative staphylococcus only) 86/373 (23%) 80/367 (22%) .68 1.1 (0.8-1.5)
Sepsis and/or meningitis late (fungal) 25/372 (7%) 20/367 (6%) .47 1.3 (0.7-2.3)
BPD (collapsed category analysis) 184/354 (52%) 182/348 (52%) .93 1.0 (0.7-1.3)
Steroids for BPD 75/403 (19%) 78/393 (20%) .66 0.9 (0.6-1.3)
Pneumothorax 24/403 (6%) 24/393 (6%) .93 1.0 (0.5-1.7)
BPD, bronchopulmonary dysplasia; GI, gastrointestinal; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; RDS, respiratory distress syndrome; ROP,
retinopathy of prematurity.
Bolded values are statistically significant.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 166, No. 2
268.e2 Reilly et al
